Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond

Future Medicinal Chemistry

Volumn 7, Issue 5, 2015, Pages 609-629

  Zindo, Frank T ^a   Joubert, Jacques ^a   Malan, Sarel F ^a  

^a UNIVERSITY OF THE WESTERN CAPE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); METAL; MONOAMINE OXIDASE INHIBITOR; PROPARGYLAMINE; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG; PARGYLINE; PROPYLAMINE;

CALCIUM HOMEOSTASIS; CHOLINESTERASE INHIBITION; DEGENERATIVE DISEASE; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; MOLECULARLY TARGETED THERAPY; NEURODEGENERATIVE DISEASES; POLYPHARMACOLOGY; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; PARGYLINE; POLYPHARMACOLOGY; PROPYLAMINES;

EID: 84930004627     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.12     Document Type: Review

References (158)

1. Experimental and Clinical Neurotoxicology. Spencer PS, Schaumburg HH, Ludolph AC (Eds). Oxford University Press, Oxford, UK (2000).
2. Bayer A, Reban J. Alzheimers Disease and Relative Conditions. MEDEA Press, Czech Republic, 192-208 (2004).
3. Dauer W, Przedborski S. Parkinsons disease: mechanisms and models. Neuron 39(6), 889-909 (2003).
4. Baker GB, Reynolds GP. Biogenic amines and their metabolites in Alzheimers disease: noradrenaline, 5-hydroxytryptamine and 5-hydroxyindole-3-Acetic acid are depleted in the hippocampus but not in substantia innominata. Neurosci. Lett. 100(1-3), 335-339 (1989).
5. Cross AJ. Serotonin in Alzheimer type dementia and other dementing illnesses. Ann. NY Acad. Sci. 600, 405-415 (1990).
6. Swerdlow RH, Khan SM. The Alzheimers disease mitochondrial cascade hypotheses: an update. Exp. Neurol. 218(2), 308-315 (2009).
7. Coyle JT, Puttfarcken P. Oxidative stress, glutamate and neurodegenerative disorders. Science 262(5134), 689-695 (1993).
8. Huang X, Moir RD, Tanzi RE, Bush AI, Rogers JT. Redoxactive metals, oxidative stress and Alzheimers disease pathology. Ann. NY Acad. Sci. 1012, 153-163 (2004).
9. Hauser RA. Future treatments for Parkinsons disease: surfing the PD pipeline. Int. J. Neurosci. 121(2), 53-62 (2011).
10. Alessandri B, Tsuchida E, Bullock RM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res. 845(2), 232-235 (1999).
11. Kamei K, Maeda N, Ogino R et al. New 5-HT1A receptor agonists possessing 1, 4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. 11(4), 595-598 (2001).
12. Collins GT, Witkin JM, Newman AH et al. Dopamine agonist-induced yawning in rats: a dopamine D3 receptormediated behavior. J. Pharmacol. Exp. Ther. 314(1), 310-319 (2005).
13. Leoacute;n R, García AG, Marco-Contelles J. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimers disease. Med. Res. Rev. 33(1), 139-189 (2013).
14. Youdim MHB, Buccafusco JJ. CNS Targets for multifunctional drugs in the treatment of Alzheimers and Parkinsons diseases. J. Neural. Transm. 112(4), 519-537 (2005).
15. Sterling J, Herzig Y, Goren T et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimers disease. J. Med. Chem. 45(24), 5260-5279 (2002).
16. Damier P, Kastner A, Agid Y, Hirsch EC. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinsons disease? Neurology 46(5), 1262-1269 (1996).
17. Matos MJ, Santana L, Janeiro P. Design, Synthesis and pharmacological evaluation of new coumarin derivatives as monoamine oxidase A and B inhibitors. ECSOC 12, 1-30 (2008).
18. Matos MJ, Vilar S, Gonzalez-Franco R et al. Novel (coumarin- 3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study. Eur. J. Med. Chem. 63, 151-161 (2013).
19. Bolea I, Gella A, Unzeta M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimers disease with monoamine oxidase inhibitors. J. Neural. Transm. 120(6), 893-902 (2013).
20. Weinreb O, Amit T, Bar-Am O, Youdim MBH. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 92(3), 330-344 (2010).
21. Youdim MBH, Bar-Am O, Yogev-Falach M et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79(1-2), 172-179 (2005).
22. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MBH, Naoi M. Neuroprotection by propargylamines in Parkinsons disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24(5), 675-682 (2002).
23. Sterling J, Herzig Y, Goren T et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimers disease. J. Med. Chem. 45(24), 5260-5279 (2002).
24. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 20(12), 2177-2179 (2006).
25. Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Cell. Mol. Neurobiol. 21(6), 555-573 (2002).
26. Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation. J. Alzheimers Dis. 21(2), 361-371 (2010).
27. Youdim MBH, Finberg JPM. Monoamine oxidase inhibitor antidepressants. In: Preclinical Psychopharmacology (Part 1). Grahame-Smith DG, Cowen PJ (Eds). Excerpta Medica, Amsterdam, 38-70 (1983).
28. Youdim MBH, Finberg JPM, Tipton KF. Amine oxidases. In:Handbook of Experimental Pharmacology. Weiner N, Trendelenburg U (Eds). Springer-Verlag, Berlin, 119-92 (1988).
29. Nicotra A, Pierucci F, Parvez H, Senatori O. Monoamine oxidase expression during development and aging. Neurotoxicology 25(1-2), 155-165 (2004).
30. Fowler JS, Volkow ND, Wang GJ et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol. Aging 18(4), 431-435 (1997).
31. Karolewicz B, Klimek V, Zhu H et al. Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei. Brain Res. 1043(1-2), 57-64 (2005).
32. Finberg JP. Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinsons disease with neuroprotective potential. Rambam Maimonides Med. J. 1(1), e0003 (2010).
33. Strydom B, Bergh JJ, Petzer JP. Inhibition of monoamine oxidase by phthalide analogues. Bioorg Med. Chem. Lett. 23(5), 1269-1273 (2013).
34. Kristal BS, Conway AD, Brown AM et al. Selective dopaminergic vulnerability: 3, 4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30(8), 924-931 (2001).
35. Burke WJ, Li SW, Chung HD et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology 25(1-2), 101-115 (2004).
36. Goedert M, Spillantini MG. A century of Alzheimers disease. Science 314(5800), 777-781 (2006).
37. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci.22, 197-217 (1999).
38. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimers disease: current status and new perspectives. Lancet Neurol. 2(9), 539-547 (2003).
39. Inestrosa NC, Alvarez A, Pérez CA et al. Acetylcholinesterase accelerates assembly of amyloidbeta- peptides into Alzheimers fibrils: possible role of the peripheral site of the enzyme. Neuron 16(4), 881-891 (1996).
40. Giacobini E. Cholinergic function and Alzheimers disease. Int. J. Geriatr. Psychiatry 18(Suppl. 1), S1-S5 (2003).
41. Li B, Stribley J, Ticu A et al. Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse. J. Neurochem. 75(3), 1320-1331 (2000).
42. Darvesh S, Hopkins D, Geula C. Neurobiology of butyrylcholinesterase. Nat. Rev. Neurosci. 4(2), 131-138 (2003).
43. Silver A. The Biology of Cholinesterases (Frontiers of Biology, Volume 36). Elsevier, North Holland, Amsterdam, 426-447 (1974).
44. Giacobini E, Spiegel R, Enz A, Veroff A, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimers disease by rivastigmine: correlation with cognitive benefit. J. Neural Trans. 109(7-8), 1053-1065 (2002).
45. Morphy JR. Historical strategies for lead generation. In:Designing Multi-Target Drugs. Morphy JR, Harris CJ (Eds). The Royal Society of Chemistry, Cambridge, UK, 114-115 (2012).
46. Pérez V, Marco JL, Fernández-Alvarez E, Unzeta M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol. 127(4), 869-876 (1999).
47. Youdim MB, Weinstock M. Molecular basis of neuroprotective activities of rasagiline and the anti- Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan- 5-YL)-ethyl methyl carbamate]. Cell Mol. Neurobiol. 21(6), 555-73 (2001).
48. Weinstock M, Bejar C, Wang RH et al. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimers disease. J. Neural Transm. Suppl. 2000(60), 157-169 (2000).
49. Weinreb O, Mandel S, Bar-Am O. et al. Multifunctional Neuroprotective Derivatives of Rasagiline as Anti- Alzheimers Disease Drugs. Neurotherapeutics. 6(1), 163-174 (2009).
50. Weinstock M, Goren T, Youdim MB. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimers disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res. 50, 216-222 (2000).
51. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid. Redox Signal. 13(6), 919-49 (2010).
52. Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimers disease treatment. Curr. Drug Targets 13(4), 483-94 (2012).
53. Sagi Y, Weinstock M, Youdim MB. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor. J. Neurochem. 86(2), 290-297 (2003).
54. OCarroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch. Pharmacol. 322(3), 198-202 (1983).
55. Green AR, Mitchell BD, Tordoff AF, Youdim MB. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 60(3), 343-349 (1977).
56. Youdim MBH, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7(4), 295-309 (2006).
57. Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann. Pharmacother. 32(1), 70-77 (1998).
58. Samadi A, Chioua M, Bolea I et al. Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimers disease. Eur. J. Med. Chem. 46(9), 4665-4668 (2011).
59. Cutillas B, Ambrosio S, Unzeta M. Neuroprotective effect of the monoamine oxidase inhibitor PF 9601N [N-(2- propynyl)-2-(5-benzyloxy-indolyl) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci. Lett. 329(2), 165-168 (2002).
60. Prat G, Pérez V, Rubí A, Casas M, Unzeta M. The novel type B MAO inhibitor PF9601N enhances the duration of L-DOPA-induced contralateral turning in 6-hydroxydopamine lesioned rats. J. Neural. Transm. 107(4), 409-417 (2000).
61. Bolea I, Juárez-Jiménez J, de los Ríos C et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]- N-methylprop-2-yn-1-Amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimers disease. J. Med. Chem. 54(24), 8251-8270 (2011).
62. Bautista-Aguilera OM, Esteban G, Chioua M et al. Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimers disease: design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridylhybrids. Drug Des. Devel. Ther. 8, 1893-1910 (2014).
63. Ellman GL, Courtney KD, Andres BJ, Feather-stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88-95 (1961).
64. Bautista-Aguilera OM, Esteban G, Bolea I et al. Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezileindolyl hybrids as multipotent cholinesterase/ monoamine oxidase inhibitors for the potential treatment of Alzheimers disease. Eur. J. Med. Chem. 75, 82-95 (2014).
65. Zhou M, Panchuk-Voloshina N. A one-step fluorometric method for the continuous measurement of monoamine oxidase activity. Anal. Biochem. 253(2), 169-174 (1997).
66. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455-461 (2010).
67. Thomas T. Monoamine oxidase B inhibitors in the treatment of Alzheimers disease. Neurobiol. Aging 21(2), 343-348 (2000).
68. Riederer P, Danyelczyk W, Grunblat E. Monoamine oxidase inhibition in Alzheimers disease. Neurotoxicology 25(1-2), 271-277 (2004).
69. Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs: ladostigil. Neurotoxic Res. 10(3-4), 181-192 (2006).
70. Tsunekawa H, Noda Y, Mouri A, Yoneda F, Nameshiba T. Synergistic effects of selegiline and donepezil on cognitive impaitment induced by amyloid beta (25-35). Behav. Brain Res 190 2 224-232(2008).
71. Camps P, Duque MD, Vázquez S et al. Synthesis and pharmacological evaluation of several ring-contracted amantadine analogs. Bioorg. Med. Chem. 16(23), 9925-9936 (2008).
72. Stone TW, Addae JI. The pharmacological manipulation of glutamate receptors and neuroprotection. Eur. J. Pharmacol. 447(2-3), 285-296 (2002).
73. Sobrado M, Loacute;pez MG, Carceller F, García AG, Roda JM. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 118(1), 107-113 (2003).
74. Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat. Rev. Drug Discov. 5(2), 160-170 (2006).
75. Greenamyre JT, OBrien CF. N-methyl-d-Aspartate antagonists in the treatment of Parkinsons disease. Arch. Neurol. 48(9), 977-981 (1991).
76. Geldenhuys WJ, Malan SF, Murugesan T, van der Schyf CJ, Bloomquist JR. Synthesis and biological evaluation of pentacyclo[5.4.0.02, 6.03, 10.05, 9]undecane derivatives as potential therapeutic agents in Parkinsons disease. Bioorg. Med. Chem. 12(7), 1799-1806 (2004).
77. Duque MD, Camps P, Torres E et al. New oxapolycyclic cage amines with NMDA receptor antagonist and trypanocidal activities. Bioorg. Med. Chem. 18(1), 46-57 (2010).
78. Torres E, Duque MD, Loacute;pez-Querol M et al. Synthesis of benzopolycyclic cage amines: NMDA receptor antagonist, trypanocidal and antiviral activities. Bioorg. Med. Chem. 20(2), 942-948 (2012).
79. Zindo FT, Barber QR, Joubert J, Bergh JJ, Petzer JP, Malan SF. Polycyclic propargylamine and acetylene derivatives as multifunctional neuroprotective agents. Eur. J. Med. Chem. 80, 122-134 (2014).
80. Mdzinarishvili A, Geldenhuys WJ, Abbruscato TJ, Bickel U, Klein J, van der Schyf CJ. NGP1-01, a lipophilic polycyclic cage amine, is neuroprotective in focal ischemia. Neurosci. Lett. 383(1-2), 49-53 (2005).
81. Geldenhuys WJ, Malan SF, Bloomquist JR, Marchand AP, van der Schyf CJ. Pharmacology and structure-Activity relationships of bioactive polycyclic cage compounds: a focus on pentacycloundecane derivatives. Med. Res. Rev. 25(1), 21-48 (2005).
82. Kiewert C, Hartmann J, Stoll J, Thekkumkara TJ, Geldenhuys WJ, Klein J. NGP1-01 is a brain permeable dual blocker of neuronal voltage-And ligand-operated calcium channels. Neurochem. Res. 31(3), 395-399 (2006).
83. Hao J, Mdzinarishvili A, Abbruscato TJ et al. Neuroprotection in mice by NGP1-01 after transient focal brain ischemia. Brain Res. 1196, 113-120 (2008).
84. Du Preez JL, Lotter AP, Guillory JK. Kineticsand mechanism of degradation of the heterocyclic cage compound NGP1-01 in aqueoussolution. Pharmazie 51, 223 (1996).
85. Du Preez JL, Lotter AP. LC-MS identification of the degradates of NGP1-01 and subsequent development of a routine stability-indicating method of analysis. Drug Dev. Ind. Pharm. 22, 1249 (1996).
86. Hollingsworth EB, McNeal ET, Burton JL, Williams RJ, Daly JW, Creveling CR. Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 3:5-monophosphategenerating systems, receptors, and enzymes. J. Neurosci. 5(8), 2240-2253 (1985).
87. Molecular Operating Environment (MOE), Version 2011.10. www.chemcomp.com
88. Joubert J, Geldenhuys WJ, Van der Schyf CJ et al. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs. ChemMedChem 7(3), 375-84 (2012).
89. Zah J, TerreBlanche G, Erasmus E, Malan SF. Physicochemical prediction of a brain-blood distribution profile in polycyclic amines. Bioorg. Med. Chem. 11(17), 3569-3578 (2003).
90. Brookes KB, Hickmott PW, Jutle KK, Schreyer CA. Introduction of pharmacophoric groups into polycyclic systems 4. aziridine, oxiran, and tertiary betahydroxyethylamine derivatives of adamantine. S. Afr. J. Chem. 45, 8-11 (1992).
91. Huang X, Cuanjungco MP, Atwood CS et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J. Biol. Chem. 274(52), 37111-37116 (1999).
92. Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K. Tyrosine hydroxylase activity in caudate nucleus from Parkinsons disease: effects of iron and phosphorylating agents. J. Neurochem. 50(1), 202-208 (1988).
93. Mounsey RB, Teismann P. Chelators in the treatment of iron accumulation in parkinsons disease. Int. J. Cell Biol. 9832, 45 (2012).
94. Dexter DT, Wells FR, Agid F, Lees AJ, Jenner P, Marsden CD. Increased nigral iron content in postmortem parkinsonian brain. Lancet 2(8569), 1219-1220 (1987).
95. Sofic E, Riederer P, Heinsen H et al. Increased iron (III) and total iron content in post mortem substantia nigra of Parkinsonian brain. J. Neural Transm. 74(3), 199-205 (1988).
96. Jenner P, Olanow CW. Understanding cell death in Parkinsons disease. Ann. Neurol. 44(3 Suppl. 1), S72-S84 (1998).
97. Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinsons disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. NY Acad. Sci. 1012, 306-325 (2004).
98. Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46(2), 254-263 (2004).
99. Gal S, Zheng H, Fridkin M, Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 95(1), 79-88 (2005).
100. Zheng H, Gal S, Weiner LM et al. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 95(1), 68-78 (2005).
101. Kupershmidt L, Weinreb O, Amit T, Mandel S, Bar- Am O, Youdim MB. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience 189, 345-358 (2011).
102. Kupershmidt L, Amit T, Bar-Am O, Youdim MB, Weinreb O. The novel multitarget iron chelating-radical scavenging compound M30 possesses beneficial effects on major hallmarks of Alzheimers disease. Antioxid. Redox Signal. 17(6), 860-77 (2012).
103. Kupershmidt L, Amit T, Bar-Am O, Weinreb O, Youdim MB. Multi-target, neuroprotective and neurorestorative M30 improves cognitive impairment and reduces Alzheimers-like neuropathology and age-related alterations in mice. Mol. Neurobiol. 46(1), 217-220 (2012).
104. Youdim MB, Kupershmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinsons disease. Parkinsonism Relat. Disord. 20(Suppl. 1), S132-S136 (2014).
105. Wang L, Esteban G, Ojima M et al. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimers disease. Eur. J. Med. Chem. 80, 543-561 (2014).
106. Zheng H, Weiner LM, Bar-Am O et al. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimers, Parkinsons, and other neurodegenerative diseases. Bioorg. Med. Chem. 13(3), 773-83 (2005).
107. Zhu W, Xie W, Pan T et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21(14), 3835-3844 (2007).
108. Fowler CJ, Tipton KF. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem. Pharmacol. 30(24), 3329-3332 (1981).
109. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelatormonoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimers disease. J. Neurochem. 100(2), 490-502 (2007).
110. Ozaita A, Olmos G, Boronat MA, Lizcano JM, Unzeta M, García-Sevilla JA. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br. J. Pharmacol. 121(5), 901-912 (1997).
111. Pérez V, Marco JL, Fernández-A lvarez E, Unzeta M. Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. Br. J. Pharmacol. 127(4), 869-876 (1999).
112. Huang CY. Determination of binding stoichiometry by the continuous variation method: the job plot. Methods Enzymol. 87, 509-525 (1982).
113. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. 14(6), 763-766 (1997).
114. Kirkinezos IG, Moraes CT. Reactive oxygen species and mitochondrial diseases. Semin. Cell Dev. Biol. 12(6), 449-457 (2001).
115. Schulz JB, Matthews RT, Muqit MM, Browne SE, Beal MF. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J. Neurochem. 64(2), 936-939 (1995).
116. Hantraye P, Brouillet E, Ferrante R et al. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat. Med. 2(9), 1017-1102 (1996).
117. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl Acad. Sci. USA 87(4), 1620-1624 (1990).
118. Avila M, Balsa MD, Fernandez-Alvarez E, Tipton KF, Unzeta M. The effect of side-chain substitution at positions 2 and 3 of the heterocyclic ring of N-Acetylenic analogues of tryptamine as monoamine oxidase inhibitors. Biochem. Pharmacol. 45(11), 2231-2237 (1993).
119. Unzeta M, Sanz E, NovelMAO-B inhibitors: potential therapeutic use of the selective MAO-B inhibitor PF9601N in Parkinsons disease. Int. Rev. Neurobiol 100, 217-236 (2011).
120. Perez V, Unzeta M. PF 9601N [N-(2-propynyl)-2-(5- benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 mice. Neurochem. Int. 42(3), 221-229 (2003).
121. Cutillas B, Ambrosio S, Unzeta M. Neuroprotective effect of the monoamine oxidase inhibitor PF9601N [N-(2-propynyl)- 2-(5-benzyloxy- indolyl) methylamine] on rat nigral neurons after 6-OH-DA striatal lesion. Neuroscience Lett. 329(2), 165-168 (2002).
122. Sanz E, Romera M, Bellik L, Marco JI, Unzeta M. Indolalkylamines derivatives as antioxidant and neuroprotective agents in an experimental model of Parkinsons disease. Med. Sci. Monit. 10(12), BR477-BR484 (2004).
123. Bellik L, Dragoni S, Pessina F, Sanz E, Unzeta M, Valoti M. Antioxidant properties of PF9601N, a novel MAO-B inhibitor: assessment of its ability to interact with reactive nitrogen species. Acta Biochim. Pol. 57(2), 235-239 (2010).
124. Sanz E, Quintana A, Battaglia V et al. Anti-Apoptotic effect of Mao-B inhibitor PF9601N [N-(2-propynyl)-2-(5- benzyloxyindolyl) methylamine] is mediated by p53 pathway inhibition in MPP+-treated SH-SY5Y human dopaminergic cells. J. Neurochem. 105(6), 2404-2417 (2008).
125. Marini S, Nannelli A, Sodini D et al. Expression, microsomal and mitochondrial activities of cytochrome P450 enzymes in brain regions from control and phenobarbital-treated rabbits. Life Sci. 80(10), 910-917 (2007).
126. Mihara T, Iwashita A, Matsuoka N. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinsons disease drugs. Behav. Brain Res. 194(2), 152-161 (2008).
127. Shook BC, Rassnick S, Osborne MC et al. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinsons disease. J. Med. Chem. 53(22), 8104-8115 (2010).
128. Mihara T, Mihara K, Yarimizu J et al. Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-Amino-3-(4-fluorophenyl) pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinsons disease and cognition. J. Pharmacol. Exp. Ther. 323(2), 708-719 (2007).
129. Dungo R, Deeks ED. Istradefylline: first global approval. Drugs 73(8), 875-882 (2013).
130. Muller CE, Ferré S. Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. Recent Pat. CNS Drug Discov. 2(1), 1-21 (2007).
131. Petzer JP, Castagnoli N Jr, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinsons disease. Neurotherapeutics 6(1), 141 (2009).
132. Pinna A, Simola N, Frau L, Morelli M. Symptomatic and neuroprotective effects of a2a receptor antagonists in Parkinsons disease. In:Adenosine: A Key Link Between Metabolism and Brain Activity. Masino S, Boison D (Eds). Springer, NY, USA, 361-384 (2013).
133. Yu L, Shen HY, Coelho JE et al. Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann. Neurol. 63(3), 338-346 (2008).
134. Al-Nuaimi SK, Mackenzie EM, Baker GB. Monoamine oxidase inhibitors and neuroprotection: a review. Am. J. Ther. 19(6), 436-448 (2012).
135. Hickey P, Stacy M. Adenosine A2A antagonists in Parkinsons disease: whats next? Curr. Neurol. Neurosci. Rep. 12(4), 376-385 (2012).
136. Koch P, Akkari R, Brunschweiger A et al. 1, 3-Dialkylsubstituted tetrahydropyrimido[1, 2-f ]purine-2, 4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases. Bioorg. Med. Chem. 21(23), 7435-7452 (2013).
137. Drabczyñska A, Müller CE, Lacher SK et al. Synthesis and biological activity of tricyclic aryloimidazo-, pyrimido-, and diazepinopurinediones. Bioorg. Med. Chem. 14(21), 7258-7281 (2006).
138. Samadi A, Valderas C, de los Ríos C et al. Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-Aminopyridine-3- carbonitriles. Bioorg. Med. Chem. 19(1), 122-133 (2011).
139. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-Acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther. 8(12), 1955-1962 (2008).
140. Rucins M, Kaldre D, Pajuste K et al. Synthesis and studies of calcium channel blocking and antioxidant activities of novel 4-pyridinium and/or N-propargyl substituted 1, 4-dihydropyridine derivatives. C. R. Chimie 17, 69-80 (2014).
141. Liu Z, Zhang H, Ye N et al. Synthesis of dihydrofuroaporphine derivatives: identification of a potent and selective serotonin 5-HT 1A receptor agonist. J. Med. Chem. 53(3), 1319-1328 (2010).
142. Bossert F, Vater W. 1, 4-Dihydropyridines - a basis for developing new drugs. Med. Res. Rev. 9(3), 291-324 (1989).
143. Triggle DJ. Calcium channel antagonists: clinical uses - past, present and future. Biochem. Pharmacol. 74(1), 1-9 (2007).
144. Duburs G, Vigante B, Plotniece A et al. Dihydropyridine derivatives as bioprotectors. Chim. Oggi. 26, 68-70 (2008).
145. Joyce JN. Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90(2-3), 231-259 (2001).
146. Pilla M, Perachon S, Sautel F et al. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400(6742), 371-375 (1999).
147. Koob GF, Caine SB. Cocaine addiction therapy - are we partially there? Nat. Med. 5(9), 993-995 (1999).
148. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a doubleblind randomized trial. Neurology 52(5), 938-943 (1999).
149. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49(3), 231-252 (1997).
150. Newman AH, Grundt P, Nader MA. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 48(11), 3663-3679 (2005).
151. Collins GT, Newman AH, Grundt P et al. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berl.) 193(2), 159-170 (2007).
152. Alessandri B, Tsuchida E, Bullock RM. The neuroprotective effect of a new serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by acute subdural hematoma in the rat. Brain Res. 845(2), 232-235 (1999).
153. Kamei K, Maeda N, Ogino R et al. New 5-HT1A receptor agonists possessing 1, 4-benzoxazepine scaffold exhibit highly potent anti-ischemic effects. Bioorg. Med. Chem. Lett. 11(4), 595-598 (2001).
154. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57(10), 1829 (2001).
155. Melamed E, Zoldan J, Friedberg G, Ziv I, Weizmann A. Involvement of serotonin in clinical features of Parkinsons disease and complications of L-DOPA therapy. Adv. Neurol. 69, 545-550 (1996).
156. Lucas G, Bonhomme N, De Deurwaerdere P, Le Moal M, Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidolinduced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl.) 131(1), 57-63 (1997).
157. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinsons disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9(Suppl. 3), 1-6 (2002).
158. Avraham Pharmaceuticals Announces Successful Interim Results in Phase 2b Study of Ladostigil for the Treatment of MCI. www.businesswire.com